Abstract
Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and young children worldwide. Lower respiratory tract infection due to RSV is one of the most common causes of hospitalization for infants, especially those born premature or with chronic lung or heart disease. Furthermore, RSV infection is an important cause of morbidity in adults, particularly in the elderly and immunocompromised individuals. The acute phase of this infection is often followed by episodes of wheezing that recur for months or years and usually lead to a physician diagnosis of asthma. RSV was discovered more than 50 years ago, and despite extensive research to identify pharmacological therapies, the most effective management of this infection remains supportive care. The trial of a formalin-inactivated RSV vaccine in the 1960s resulted in priming the severe illness upon natural infection. Currently, Palivizumab is the only available option for RSV prophylaxis, and because of restricted clinical benefits and high costs, it has been limited to a group of high-risk infants. There are several ongoing trials in preclinical, Phase-I, Phase-II, or Phase-III clinical stages for RSV vaccine development based on various strategies. Here ...Continue Reading
Citations
Aug 16, 2017·Journal of Clinical Laboratory Analysis·Zhanhu ZhangHaibo Li
Jan 25, 2018·Viruses·Jennifer A Pickens, Ralph A Tripp
Feb 7, 2018·Pediatric Pulmonology·Maarten O BlankenXavier Carbonell-Estrany
Oct 20, 2018·Minerva pediatrica·Antonio Del VecchioFrancesco Raimondi
Nov 30, 2018·American Journal of Physiology. Lung Cellular and Molecular Physiology·Carrie C SmallcombeFariba Rezaee
Jul 16, 2019·PLoS Pathogens·Harrison G JonesJason S McLellan
May 14, 2019·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Ajay SheshadriSaadia A Faiz
Jun 23, 2020·Expert Opinion on Pharmacotherapy·Susanna EspositoNicola Principi
Jan 2, 2019·Vaccines·Rika GomiStefan Worgall
Apr 16, 2019·Frontiers in Cellular and Infection Microbiology·Orlando A AcevedoAlexis M Kalergis
Oct 28, 2019·Frontiers in Immunology·Lydia J AthertonRalph A Tripp
Aug 4, 2020·Antiviral Chemistry & Chemotherapy·Elena Margret ThornhillDavid Verhoeven
Mar 8, 2020·Archives of Virology·Hai LiWenbo Xu
Jan 18, 2020·Vaccines·Federica BarbatiChiara Azzari
May 12, 2020·Frontiers in Microbiology·Longping V TseRalph S Baric
Mar 30, 2018·The Journal of Antimicrobial Chemotherapy·Carmen MirabelliDirk Jochmans
Feb 13, 2020·Frontiers in Pharmacology·Cunsi ShenXia Zhao
Jul 10, 2020·American Journal of Physiology. Lung Cellular and Molecular Physiology·Carrie C SmallcombeFariba Rezaee
Jun 25, 2020·IScience·Sudipta DasPrabir Ray
Feb 27, 2021·Tissue Barriers·Debra T LinfieldFariba Rezaee
Mar 12, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Linlin YuXiaoping Jing
Jul 8, 2020·ACS Infectious Diseases·Adriana Zardini BuzattoLiang Li
May 22, 2021·Expert Review of Proteomics·Morgan Mann, Allan R Brasier
Dec 1, 2017·Journal of Virology·Kok Fei ChanPatrick C Reading
Aug 11, 2018·Pediatrics·Andrea A Beckhaus, Jose A Castro-Rodriguez